Cardiac Aspect of Coronavirus Disease 2019 (COVID-19) in Children
Journal of Pediatric Nephrology,
Vol. 8 No. 2 (2020),
2 June 2020
,
Page 1-6
https://doi.org/10.22037/jpn.v8i2.30078
Abstract
Coronavirus disease 2019 (COVID-19) is a global pandemic with more than a million confirmed cases of COVID-19 and more than 130,000 deaths reported worldwide. The major morbidity and mortality from COVID-19 are large because of acute viral pneumonitis that evolves to acute respiratory distress syndrome. Cardiac injury is one of the common complications of COVID-19. Furthermore, preexisting cardiovascular disease is one of the important risk factors for mortality among the patients. Evidence of cardiac involvement is common among patients hospitalized with COVID-19, but the causes of myocardial injury have not been completely explained. COVID-19 appears to be milder in children than in adults and fewer children seem to have developed severe respiratory distress. The aim of this article is a brief review of cardiovascular involvement in COVID-19 with a focus on cardiac disease in children.
Keywords: COVID-19; Corona virus disease 2019; Cardiac complication; Cardiovascular disease; Arrhythmia; Mortality; Child.
- COVID-19
- Cardiac complication
- Cardiovascular disease
- Arrhythmia
- Mortality children
How to Cite
References
Li W, Hulswit RJG, Kenney SP, et al. Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility. Proc Natl Acad Sci U S A. 2018;115(22):E5135-E5143.
Guan WJ, Ni ZY, Hu Y, et al. china medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. doi:10.1056/NEJMoa2002032
Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. Published online March 5, 2020. doi:10.1002/ppul.24718
4- Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020 Mar 23. doi: 10.1111/apa.15270.
Zhang Y. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020. Chinese Journal of Epidemiology (by The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team)
Alhogbani T. Acute myocarditis associated with novel Middle East respiratory syndrome coronavirus. Ann Saudi Med 2016; 36:78-80.
Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767-72.
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi:10.1001/jama.2020.1585.
Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med.2020:S2213-2600(20)30079-5. doi:10.1016/S22132600(20)30079-5
Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. Published online March 25, 2020. doi:10.1001/jamacardio.2020.0950
Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on etiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34:2636.
Zheng Y-Y, Ma Y-T, Zhang J-Y and Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. March 5, 2020. doi: 10.1038/s41569-020-0360-5.
Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill Patients with COVID-19 in Washington State. JAMA. 2020
Guo T, Fan Y, Chen M, et al. Association of cardiovascular disease and myocardial injury with outcomes of patients hospitalized with 2019-coronavirus disease (COVID-19). JAMA Cardiol. Published online March 27, 2020. doi:10.1001/ jamacardio.2020.1017.
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507-13.
Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506.
Cherian R, Poh K. At the ‘heart’ of the COVID-19 outbreak: early cardiac implications and mitigating strategies. Singapore Med J 2020, 1–6 doi.org/10.11622/smedj.2020042
Kevin J. Clerkin KJ, Fried JA, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020 Mar 21. doi: 10.1161/CIRCULATIONAHA.120.046941
Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. March 11, 2020. doi: 10.1016/S0140-6736(20)30566-3.
Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. March 16, 2020. doi: 10.1093/eurheartj/ehaa190.
Zeng JH, Liu YX, Yuan J, et al. First Case of COVID-19 Infection with Fulminant Myocarditis Complication: Case Report and Insights. preprints. 2020; 2020030180. doi:10.20944/preprints202003.0180.v1.
Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. 2020 Mar 27. doi: 10.1001/jamacardio.2020.1286.
Guo J, Huang Z, Lin L, Lv J .Coronavirus Disease 2019 (COVID‐19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219. doi: 10.1161/JAHA.120.016219.
Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020. doi: 10.1111/apa.15270.
CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-346. doi:10.15585/mmwr.mm6912e2
Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clinical Infectious Diseases, ciaa198, https://doi.org/10.1093/cid/ciaa198 Published: 28 February 2020
Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics 2020.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033.
Brodin P. Why is COVID-19 so mild in children? Acta Paediatr. 2020 Mar 25. doi: 10.1111/apa.15271.
CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:422.
Liu K, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020.
Lakkireddy DR, Chung MK, Gopinathannair R, et al. Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation 2020.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020. doi:10.1007/s00134-020-05991-x
Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol 2020.
Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap! Circulation. 2020 Apr 14. doi: 10.1161/CIRCULATIONAHA.120.047293
Haeusler IL, Chan XHS, Guérin PJ, White NJ. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Med 2018; 16:200.
Fossa AA, Wisialowski T, Duncan JN, et al. Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg 2007; 77:929.
Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. Circulation 2020.
Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. Eur Heart J. 2017;38:1717-1727.
Lazzerini PE, Laghi-Pasini F, Boutjdir M, et al. Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathies. Nat Rev Immunol. 2019;19:63-64.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.
Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation 2020.
de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2015; 132:S526-542.
-Li B, Yang J, Zhuo F, et al. Prevalence and impact of cardiovascular metabolic disease on COVID-19 in china. Clin Res Cardiol .2020
Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med. 2020 Mar 24;8(1):e35.
- Abstract Viewed: 170 times
- PDF Downloaded: 219 times